Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sutent Adjunctive Treatment of Differentiated Thyroid Cancer.

Trial Profile

Sutent Adjunctive Treatment of Differentiated Thyroid Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2018

At a glance

  • Drugs Sunitinib (Primary) ; Iodine radioactive
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms IIT Sutent
  • Most Recent Events

    • 24 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 28 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Mar 2014 Planned number of patients changed from 46 to 35 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top